Skip to content
glenmark_logo_2026_big_c
Menu Close
  • About us
    • Our Journey
    • Board of Directors
    • Leadership
    • Governance
    • Manufacturing
    • R&D
  • Innovation
    • Overview
    • Pipeline
    • Partnerships
  • Products
    • Portfolio
    • Top Products
  • Responsibility
    • Corporate Social Responsibility
    • Sustainability
  • Investors
    • Financials
    • Disclosures under Regulation 46 of SEBI LODR
    • Investor Resources
    • Other Announcements
  • News
    • Press Release
    • Media Library
    • Snapshots
  • Careers
    • Life at Glenmark
    • Glenmark Center for Learning
    • Join Us
  • About us
    • Our Journey
    • Board of Directors
    • Leadership
    • Governance
    • Manufacturing
    • R&D
  • Innovation
    • Overview
    • Pipeline
    • Partnerships
  • Products
    • Portfolio
    • Top Products
  • Responsibility
    • Corporate Social Responsibility
    • Sustainability
  • Investors
    • Financials
    • Disclosures under Regulation 46 of SEBI LODR
    • Investor Resources
    • Other Announcements
  • News
    • Press Release
    • Media Library
    • Snapshots
  • Careers
    • Life at Glenmark
    • Glenmark Center for Learning
    • Join Us
Menu Close
  •  Global
    • India 
    • US 
    • Canada canada_flag
    • Europe   
    • Emerging Markets
      • Asia – Pacific
      • Latin America
      • Middle East & Africa
      • Russia & CIS
  •  Global
    • India 
    • US 
    • Canada canada_flag
    • Europe   
    • Emerging Markets
      • Asia – Pacific
      • Latin America
      • Middle East & Africa
      • Russia & CIS
  • Global

More results...

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
page
Connect with Us
glenmark_logo_2026_big_c
  • About us
    • Our journey
    • Board of Directors
    • Leadership Team
    • Governance
    • Manufacturing
    • R&D Locations
  • Innovation
    • Overview
    • Pipeline
    • Partnerships
  • Products
    • Portfolio
    • Top Products
  • Responsibility
    • Corporate Social Responsibility
    • Sustainibility
  • Investors
    •  Financials
      • Quarterly Results
      • Investor Presentations
      • Annual Report
    • Disclosure under Regulation 46 of SEBI (LODR) Regulations, 2015
    • Investor Resources
    •  Other announcements
      • 2026
      • 2025
      • 2024
      • 2023
  • News
    •  Press Release
      • 2026
      • 2025
      • 2024
      • 2023
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
    • Media Library
    • Snapshots
  • Careers
    • Life at Glenmark
    • Glenmark Center for Learning
    • Join Us
  • Contact Us
  • IGI
  • Global
    • India   
    • U.S   
    • Canada   canada_flag
    • Europe   
    • Emerging Markets
      • Asia -Pacific
      • Latin America
      • Middle East & Africa
      • Russia & CIS
  • About us
    • Our journey
    • Board of Directors
    • Leadership Team
    • Governance
    • Manufacturing
    • R&D Locations
  • Innovation
    • Overview
    • Pipeline
    • Partnerships
  • Products
    • Portfolio
    • Top Products
  • Responsibility
    • Corporate Social Responsibility
    • Sustainibility
  • Investors
    •  Financials
      • Quarterly Results
      • Investor Presentations
      • Annual Report
    • Disclosure under Regulation 46 of SEBI (LODR) Regulations, 2015
    • Investor Resources
    •  Other announcements
      • 2026
      • 2025
      • 2024
      • 2023
  • News
    •  Press Release
      • 2026
      • 2025
      • 2024
      • 2023
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
    • Media Library
    • Snapshots
  • Careers
    • Life at Glenmark
    • Glenmark Center for Learning
    • Join Us
  • Contact Us
  • IGI
  • Global
    • India   
    • U.S   
    • Canada   canada_flag
    • Europe   
    • Emerging Markets
      • Asia -Pacific
      • Latin America
      • Middle East & Africa
      • Russia & CIS

GCCL Transaction Completion Letter

  • Post author:glenmark2025
  • Post published:November 1, 2025
  • Post category:

Continue ReadingGCCL Transaction Completion Letter

Glenmark Pharmaceuticals Inc., USA to launch Ropivacaine Hydrochloride Injection USP, 40 mg/20 mL (2mg/mL), 150 mg/30 mL (5 mg/mL), and 200 mg/20 mL (10 mg/mL) Single-Dose Vials

  • Post author:glenmark2025
  • Post published:October 23, 2025
  • Post category:

Continue ReadingGlenmark Pharmaceuticals Inc., USA to launch Ropivacaine Hydrochloride Injection USP, 40 mg/20 mL (2mg/mL), 150 mg/30 mL (5 mg/mL), and 200 mg/20 mL (10 mg/mL) Single-Dose Vials

Newspaper Advertisement – Interim Dividend

  • Post author:glenmark2025
  • Post published:September 30, 2025
  • Post category:

Continue ReadingNewspaper Advertisement – Interim Dividend

Outcome of Board Meeting held on 26th September, 2025

  • Post author:glenmark2025
  • Post published:September 26, 2025
  • Post category:

Continue ReadingOutcome of Board Meeting held on 26th September, 2025

Glenmark Strengthens Oncology Portfolio with Hengrui’s HER2 Targeting ADC For Multiple Regions

  • Post author:glenmark2025
  • Post published:September 24, 2025
  • Post category:

Continue ReadingGlenmark Strengthens Oncology Portfolio with Hengrui’s HER2 Targeting ADC For Multiple Regions

Board Meeting Intimation

  • Post author:glenmark2025
  • Post published:September 22, 2025
  • Post category:

Continue ReadingBoard Meeting Intimation

Credit Rating Rationale – CRISIL

  • Post author:glenmark2025
  • Post published:September 19, 2025
  • Post category:

Continue ReadingCredit Rating Rationale – CRISIL

Transfer of the Company’s Consumer Care business

  • Post author:glenmark2025
  • Post published:September 15, 2025
  • Post category:

Continue ReadingTransfer of the Company’s Consumer Care business

Intimation Regarding Upfront Payment Received

  • Post author:glenmark2025
  • Post published:September 9, 2025
  • Post category:

Continue ReadingIntimation Regarding Upfront Payment Received

Glenmark Initiates a Multi-Country Phase 3 Clinical Trial for Envafolimab in Resectable Stage III Non-Small Cell Lung Cancer

  • Post author:glenmark2025
  • Post published:September 5, 2025
  • Post category:

Continue ReadingGlenmark Initiates a Multi-Country Phase 3 Clinical Trial for Envafolimab in Resectable Stage III Non-Small Cell Lung Cancer
  • Go to the previous page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 8
  • Go to the next page
glenmark_logo_2026_big_c

Glenmark Pharmaceuticals Ltd. is a research‐led, global pharmaceutical company, having a presence across Branded, Innovative, and Generics segments with a focus on therapeutic areas of respiratory, dermatology and oncology

Linkedin-in Instagram Youtube

About us

  • Our Journey
  • Board of Directors
  • Leadership
  • Governance
  • Manufacturing
  • R&D

Innovation

  • Overview
  • Pipeline
  • Partnerships

Products

  • Portfolio
  • Top Brands

Responsibility

  • Corporate Social Responsibility
  • Sustainability

Investors

  • Financials
  • Disclosures under Regulation 46
    of SEBI LODR
  • Investor Resources
  • Other announcements

News

  • Press Release
  • Media Library
  • Snapshots

Careers

  • Life at Glenmark
  • Glenmark Centre for Learning
Join Us

CAUTION NOTICE REGARDING FRAUDULENT RECRUITMENT

This is to notify to the public that certain unscrupulous persons, purporting to be part of and/or being authorised by the human resources department of Glenmark Pharmaceuticals Limited (“Glenmark”) are fraudulently offering jobs via certain websites/or through telephone calls, SMS or fake letters and asking the prospective job aspirants to appear for a face-to-face interview for a job opening with Glenmark and/or to pay a fee for securing a job with Glenmark. We wish to caution the public that Glenmark does not collect any monies or any other valuables as a pre or post-employment requirement.

Click Here to Know More        Click Here to Join Us

Download Factsheet
  • Privacy Portal
  • Terms & Conditions
  • Report a Concern
  • Report an Adverse Event
  • Investigator Initiated Trials
© 2026 Glenmark Pharmaceuticals Ltd. All Rights Reserved.
  • About Us
  • Innovation
  • Products
  • Responsibility
  • Investors
  • News
  • Careers
  • Terms & Conditions
  • Report a Concern
  • Report an Adverse Event
  • Investigator Initiated Trials
  • Privacy Portal
Download Factsheet
Linkedin-in Instagram Youtube
© 2026 Glenmark Pharmaceuticals Ltd.
All Rights Reserved.
  • About us
    • Our journey
    • Board of Directors
    • Leadership Team
    • Governance
    • Manufacturing
    • R&D Locations
  • Innovation
    • Overview
    • Pipeline
    • Partnerships
  • Products
    • Portfolio
    • Top Products
  • Responsibility
    • Corporate Social Responsibility
    • Sustainibility
  • Investors
    •  Financials
      • Quarterly Results
      • Investor Presentations
      • Annual Report
    • Disclosure under Regulation 46 of SEBI (LODR) Regulations, 2015
    • Investor Resources
    •  Other announcements
      • 2026
      • 2025
      • 2024
      • 2023
  • News
    •  Press Release
      • 2026
      • 2025
      • 2024
      • 2023
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
    • Media Library
    • Snapshots
  • Careers
    • Life at Glenmark
    • Glenmark Center for Learning
    • Join Us
  • Contact Us
  • IGI
  • Global
    • India   
    • U.S   
    • Canada   canada_flag
    • Europe   
    • Emerging Markets
      • Asia -Pacific
      • Latin America
      • Middle East & Africa
      • Russia & CIS
Type your search

CAUTION NOTICE REGARDING FRAUDULENT RECRUITMENT

This is to notify to the public that certain unscrupulous persons, purporting to be part of and/or being authorised by the human resources department of Glenmark Pharmaceuticals Limited (“Glenmark”) are fraudulently offering jobs via certain websites/or through telephone calls, SMS or fake letters and asking the prospective job aspirants to appear for a face-to-face interview for a job opening with Glenmark and/or to pay a fee for securing a job with Glenmark. We wish to caution the public that Glenmark does not collect any monies or any other valuables as a pre or post-employment requirement.

Click Here to Know More        Click Here to Join Us